---
figid: PMC6317954__CAS-110-23-g004
figtitle: Metformin combined with Abs or small molecular inhibitors in cancer treatment
organisms:
- Homo sapiens
- Mus musculus
- Syringa vulgaris
pmcid: PMC6317954
filename: CAS-110-23-g004.jpg
figlink: /pmc/articles/PMC6317954/figure/cas13849-fig-0004/
number: F4
caption: Mechanisms of metformin combined with Abs or small molecular inhibitors in
  cancer treatment. Metformin activates the adenosine monophosphate activated protein
  kinase (AMPK) pathway, eventually causing inhibition of the mTOR pathway. Metformin
  also indirectly reduces Akt activation, through insulin‐mediated insulin receptor
  (IR) and the insulin‐like growth factor‐1 receptor (IGF‐1R)/IR hybrid which activates
  the PI3/Akt/mTOR and RAS/RAF/MAPK/ERK pathways. These pathways are also inactivated
  by Abs or small molecule inhibitors. Thus, metformin shows synergy with targeted
  drugs to reduce protein synthesis and cellular proliferation. EGFR, epidermal growth
  factor receptor; HER2, human epidermal growth factor receptor 2; IGF‐1, insulin‐like
  growth factor‐1; IRS, insulin/insulin‐like growth factor‐1 receptor substrate; Shc,
  Src homology 2/alpha‐collagen related protein; VEGFR, vascular endothelial growth
  factor receptor
papertitle: Novel application of metformin combined with targeted drugs on anticancer
  treatment.
reftext: Jun Deng, et al. Cancer Sci. 2019 Jan;110(1):23-30.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9741034
figid_alias: PMC6317954__F4
figtype: Figure
organisms_ner:
- Homo sapiens
- Mus musculus
redirect_from: /figures/PMC6317954__F4
ndex: 5b4176f5-dec2-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6317954__CAS-110-23-g004.html
  '@type': Dataset
  description: Mechanisms of metformin combined with Abs or small molecular inhibitors
    in cancer treatment. Metformin activates the adenosine monophosphate activated
    protein kinase (AMPK) pathway, eventually causing inhibition of the mTOR pathway.
    Metformin also indirectly reduces Akt activation, through insulin‐mediated insulin
    receptor (IR) and the insulin‐like growth factor‐1 receptor (IGF‐1R)/IR hybrid
    which activates the PI3/Akt/mTOR and RAS/RAF/MAPK/ERK pathways. These pathways
    are also inactivated by Abs or small molecule inhibitors. Thus, metformin shows
    synergy with targeted drugs to reduce protein synthesis and cellular proliferation.
    EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor
    2; IGF‐1, insulin‐like growth factor‐1; IRS, insulin/insulin‐like growth factor‐1
    receptor substrate; Shc, Src homology 2/alpha‐collagen related protein; VEGFR,
    vascular endothelial growth factor receptor
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IGF1
  - ERBB2
  - IGF1R
  - KDR
  - FLT1
  - FLT4
  - EGFR
  - POU2F1
  - SLC22A1
  - SHC1
  - SHC2
  - SHC3
  - SHC4
  - KRAS
  - HRAS
  - NRAS
  - IARS1
  - IRS1
  - IRS2
  - IRS4
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PRKAA1
  - PRKAA2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - EPHB2
  - RPS6KB1
  - RPS6KB2
  - EIF4EBP1
  - Igf1
  - Erbb2
  - Egfr
  - Pou2f1
  - Slc22a1
  - Shc1
  - ras
  - Hras
  - Kras
  - Rem1
  - Pik3r1
  - Zhx2
  - Akt1
  - Mtor
  - Mdk
  - Ephb2
  - Mapk1
  - Rps6kb1
  - Eif4ebp1
  - Igf1r
  - Metformin
  - XGefitinib
  - Sorafenib
  - Everolimus
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
